Osamu Yokoyama Selected Research

Cerebral Infarction

8/2017	Nerve growth factor release from the urothelium increases via activation of bladder C-fiber in rats with cerebral infarction.
12/2011	Co-administration of an α(1) -blocker improves the efficacy and safety of antimuscarinic agents in rats with detrusor overactivity.
6/2011	Antimuscarinics suppress adenosine triphosphate and prostaglandin E2 release from urothelium with potential improvement in detrusor overactivity in rats with cerebral infarction.
1/2011	Modulation of stretch evoked adenosine triphosphate release from bladder epithelium by prostaglandin E₂.
4/2010	Zolpidem increases bladder capacity and decreases urine excretion in rats.
2/2010	Improvement in neurogenic detrusor overactivity by peripheral C fiber's suppression with cyclooxygenase inhibitors.
1/2010	Pharmacological and genetic analysis of mechanisms underlying detrusor overactivity in rats.
12/2007	Effects of antimuscarinics on voiding function after cerebral infarction in a rat model of overactive bladder.
3/2007	Effects of opioid subtypes on detrusor overactivity in rats with cerebral infarction.
1/2006	Improvement of bladder storage function by alpha1-blocker depends on the suppression of C-fiber afferent activity in rats.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Osamu Yokoyama Research Topics

Disease

29	Overactive Urinary Bladder (Overactive Bladder) 11/2021 - 04/2004
17	Cerebral Infarction 08/2017 - 01/2002
14	Neoplasms (Cancer) 04/2021 - 05/2004
13	Nocturia 11/2021 - 04/2010
13	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 01/2019 - 09/2006
12	Lower Urinary Tract Symptoms 01/2018 - 09/2008
11	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 01/2011
10	Urinary Incontinence 11/2021 - 04/2014
6	Urinary Retention 09/2021 - 11/2007
6	Renal Cell Carcinoma (Grawitz Tumor) 01/2021 - 09/2011
6	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 08/2017 - 11/2002
5	Spinal Cord Injuries (Spinal Cord Injury) 09/2021 - 02/2004
5	Carcinoma (Carcinomatosis) 01/2021 - 01/2011
5	Inflammation (Inflammations) 10/2020 - 02/2010
5	Polyuria 05/2015 - 04/2011
4	Stress Urinary Incontinence 01/2021 - 11/2013
4	Neoplasm Metastasis (Metastasis) 01/2021 - 01/2013
3	Urinary Bladder Neck Obstruction (Bladder Neck Obstruction) 01/2019 - 11/2007
2	Hematuria 09/2021 - 05/2008
2	Hypertension (High Blood Pressure) 01/2018 - 11/2015
2	Constipation 01/2018 - 04/2014
2	Ataxia (Dyssynergia) 11/2016 - 02/2004
1	Hypoxia (Hypoxemia) 06/2022
1	Ischemia 06/2022
1	Pyelonephritis 12/2021
1	Hypoalbuminemia 12/2021
1	Diarrhea 12/2021
1	Hemorrhage 09/2021
1	Multiple Sclerosis 09/2021
1	Epididymitis 09/2021
1	Autonomic Dysreflexia 09/2021

Drug/Important Bio-Agent (IBA)

9	Muscarinic AntagonistsIBA 01/2019 - 11/2005
8	Cholinergic Antagonists (Anticholinergics)IBA 01/2021 - 10/2009
7	Tadalafil (Cialis)FDA Link 01/2020 - 02/2013
5	Hormones (Hormone)IBA 01/2021 - 05/2004
5	resiniferatoxinIBA 01/2019 - 11/2005
5	propiverineIBA 01/2018 - 04/2011
5	Solifenacin Succinate FDA Link 10/2015 - 07/2011
5	imidafenacinIBA 05/2015 - 06/2011
5	Tamsulosin (Flomax)FDA LinkGeneric 01/2014 - 04/2011
4	Docetaxel (Taxotere)FDA Link 10/2019 - 01/2011
4	naftopidilIBA 01/2019 - 01/2006
3	Type A Botulinum Toxins (Botox)FDA Link 11/2021 - 03/2020
3	Prostate-Specific Antigen (Semenogelase)IBA 11/2021 - 05/2013
3	Botulinum Toxins (Botulinum Toxin)IBA 09/2021 - 03/2020
3	Polysaccharides (Glycans)IBA 01/2021 - 11/2015
3	Sialyl Lewis X AntigenIBA 01/2021 - 11/2015
3	LigandsIBA 01/2021 - 10/2012
3	N- (4- ((5- (hydroxy(phenyl)methyl)pyrrolidin- 2- yl)methyl)phenyl)- 4- oxo- 4,6,7,8- tetrahydropyrrolo(1,2- a)pyrimidine- 6- carboxamideIBA 01/2021 - 01/2019
3	Phosphodiesterase 5 InhibitorsIBA 01/2020 - 10/2015
3	salicylhydroxamic acid (SHAM)IBA 01/2019 - 12/2007
3	mirabegronIBA 01/2019 - 06/2014
3	Therapeutic UsesIBA 01/2018 - 01/2011
3	Tolterodine Tartrate (Detrol)FDA Link 04/2014 - 11/2005
2	E-SelectinIBA 01/2021 - 11/2015
2	Gonadotropin-Releasing Hormone (GnRH)FDA Link 01/2021 - 05/2013
2	CA-19-9 Antigen (CA 19-9 Antigen)IBA 01/2021 - 11/2015
2	CarbohydratesIBA 01/2021 - 10/2017
2	C-Reactive ProteinIBA 10/2020 - 01/2019
2	Gonadal Steroid Hormones (Sex Hormones)IBA 01/2020 - 09/2008
2	DNA (Deoxyribonucleic Acid)IBA 11/2019 - 06/2004
2	Dinoprostone (PGE2)FDA Link 01/2018 - 06/2011
2	fesoterodine FDA Link 01/2018 - 04/2014
2	Proteins (Proteins, Gene)FDA Link 10/2017 - 02/2010
2	Nerve Growth Factor (NGF)IBA 08/2017 - 11/2010
2	Halothane (Fluothane)FDA Link 08/2017 - 05/2003
2	Monoclonal AntibodiesIBA 11/2015 - 10/2012
2	oxybutynin (Tavor)FDA LinkGeneric 07/2015 - 04/2014
2	silodosin FDA Link 01/2014 - 09/2006
2	Adrenergic Receptors (Adrenergic Receptor)IBA 11/2013 - 10/2008
2	Prednisolone (Predate)FDA LinkGeneric 09/2013 - 05/2013
2	Paclitaxel (Taxol)FDA LinkGeneric 05/2013 - 03/2011
2	Carboplatin (JM8)FDA LinkGeneric 05/2013 - 03/2011
2	Cisplatin (Platino)FDA LinkGeneric 01/2013 - 03/2011
2	Sunitinib (Sutent)FDA Link 11/2011 - 09/2011
2	Pharmaceutical PreparationsIBA 06/2011 - 05/2003
2	Adenosine Triphosphate (ATP)IBA 06/2011 - 11/2002
2	Cyclooxygenase InhibitorsIBA 01/2011 - 02/2010
2	N-Methylaspartate (NMDA)IBA 01/2010 - 01/2002
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2010 - 01/2002
2	Glutamate Receptors (Glutamate Receptor)IBA 01/2010 - 04/2004
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2010 - 07/2005
2	Messenger RNA (mRNA)IBA 05/2003 - 01/2002
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 06/2022
1	8-Hydroxy-2'-DeoxyguanosineIBA 06/2022
1	CytokinesIBA 06/2022
1	Amyloid (Amyloid Fibrils)IBA 12/2021
1	AA amyloidosisIBA 12/2021

Therapy/Procedure

18	Therapeutics 03/2021 - 05/2004
6	Drug Therapy (Chemotherapy) 10/2019 - 03/2011
5	Castration 01/2021 - 05/2013
2	Conservative Treatment 10/2017 - 01/2010
2	Anesthesia 08/2017 - 05/2003
2	Lasers (Laser) 05/2017 - 06/2013
2	Brachytherapy 01/2016 - 01/2014
2	Orchiectomy (Orchidectomy) 04/2015 - 05/2003
2	Nephrectomy 11/2013 - 11/2011
2	Combination Drug Therapy (Combination Chemotherapy) 09/2013 - 03/2011
2	Prostatectomy (Retropubic Prostatectomy) 05/2013 - 05/2004
1	Injections 09/2021